This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes the:
- A decision made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
- reasons for that final decision; and
- date of effect of the decision.
Final decision and reasons
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.
Contents
- 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
- 2 Final decision in relation to psilocybine and MDMA
- 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #38, June 2022)
- 3.1 Final decision in relation to cetirizine
- 3.2 Final decision in relation to budesonide
- 3.3 Final decision in relation to apronal (allylisopropylacetylurea)
- 4 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #31, June 2022)
- 4.1 Final decision in relation to helional
- 4.2 Final decision in relation to hydroxypinacolone retinoate (HPR)
- 4.3 Final decision in relation to MDMA and MDA nomenclature
- 5 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #34, June 2022)
- 5.1 Final decision in relation to dichloromethane
- 5.2 Final decision in relation to ipflufenoquin
- 6 Amendments to the Poisons Standard in relation to New Chemical Entities (NCEs)
- 6.1 Avacopan
- 6.2 Deucravacitinib
- 6.3 Edaravone
- 6.4 Lenacapavir
- 6.5 Patisiran
- 6.6 Tirzepatide
- 7 Amendments to the Poisons Standard made as delegate-only decisions
- 7.1 Final decision in relation to fenpropidin
- 7.2 Final decision in relation to fluralaner